Delphi consensus on Thoroughbred yearling sales endoscopy in Australasia.

By 2010 (for review see,), the jury had returned, and the verdict was clear. Deep Brain Stimulation was not only safe but was effective in improving good ON time in patients with advanced Parkinson's Disease (PD). There were a few caveats that seemed reasonable, such as the need for a clear response to levodopa, exclusion of untreated or unresponsive psychiatric symptoms (e.g., psychosis, severe depression, impulsivity), exclusion of severe axial impairment (e.g., balance issues) and unfavourable neuroimaging (e.g., severe atrophy). However, at the same time, the presence of significant cognitive impairment was also promulgated into clinical practice as part of the DBS doctrine. Whilst the exclusion of those patients with dementia who lack capacity appears to have a clear rationale, the extension of this rule to a broader population of cognitively impaired patients, more likely reflected the constraints and eligibility requirements of the clinical trial protocols used in the initial landmark studies, rather than clear evidence of potential harm. Indeed, multiple studies have indicated that aside from a consistent drop on the assessment of verbal fluency following DBS, there is no evidence for an accelerated cognitive decline. A 69 year old patient attends his follow up appointment with his wife complaining of significant wearing off and dyskinesia. He has had 9 years of disease and is taking a monoamine oxidase inhibitor, a catechol-O-methyltransferase inhibitor, 200 mg of amantadine, the maximum dose of a dopamine agonist and 1000 mg of levodopa in a day. His wife raises concerns about a deterioration in his cognitive abilities over the past year and the patient reports some well formed but non-frightening visual hallucinations. His bedside testing reveals a Montreal Cognitive Assessment of 19/30. Despite having no surgical contraindications for DBS, no referral was made to the local service due to concerns about his cognitive decline and future neuropsychiatric prognosis. The patient was assessed for all available infusion therapies. He did not want to consider intestinal gel preparations due to concerns relating to perceived high rates of device related complications, which can affect around 70% of cases. He developed more florid hallucinations with subcutaneous fos-levodopa, an adverse event that has been reported in 17% of patients within 12 months and was unable to tolerate subcutaneous apomorphine infusion due to skin nodules, which can affect over 50%. In an effort to improve motor symptoms, his levodopa dose was increased but this resulted in a fractured a hip when he fainted with orthostatic hypotension, reminding us all about the importance of screening for osteoporosis in this population. Hospitalisation to repair his fractured hip was associated with a prolonged delirium and a step decline in cognition. After extensive rehabilitation, the patient was discharged home but the reduced dose of dopaminergic therapy to control orthostatic hypotension, psychosis and somnolence resulted in poor mobility and caregiver stress associated with urinary incontinence. At the age of 70 years, the patient was transitioned into institutional care.